• Artrya signs first partnership in the US as it looks to commercialise
  • EZZ Life Sciences sets up a store on TikTok China
  • Oceania buys two premium villages in Auckland

AI-based cardiac software solution developer, Artrya Limited (ASX: AYA), just announced its first clinical partnership in the US, signing with Alabama-based Huntsville Heart Center Inc.

Huntsville is a leading US company in coronary computed tomography angiography (CCTA) that treats more than 80,000 cardiac patients per year.

The two companies will conduct a study to determine the efficacy of Artrya’s technology, the Salix Coronary Anatomy.

Salix is an AI-based software capable of analysing cardiac CT scans to report a combination of coronary disease biomarkers, including components of high-risk plaque.

It was Artrya’s first clinical partnership in the US which could potentially pave the way for commercialisation in the country.

Trial results are expected to be completed by October this year.

Meanwhile, health supplements company EZZ Life Sciences (ASX:EZZ) has established a global overseas flagship store on the Douyin platform, a Chinese name for TikTok.

Douyin has over 670 million active users per month, and has overtaken Tmall Global as the leading short form video and social engagement platform in China.

EZZ believes the newly created EZZ International store on Douyin will significantly increase EZZ’s market reach and distribution capabilities in the country.

The next step will see EZZ products delivered to Douyin’s free trade zone for distribution from May 2022 onwards, which includes supplements and functional foods.


Artyra and EZZ share prices today:


Other ASX health stocks news today

Premium healthcare network provider Oceania Healthcare (ASX:OCA) is set to acquire two premium villages, Remuera Rise and Bream Bay Villages, in New Zealand.

Remuera is a prestigious retirement village in Auckland, while Bream Bay is a an 83-unit complex located in Northland, NZ.

Oceania has also entered into an option agreement to buy 6.7 hectares next to the Bream Bay village site.

The company says funding will be met with existing cash and debt.

Meanwhile, the FDA has approved Dimerix’s (ASX:DXB) ACTION3 Phase 3 clinical study, paving the way for patient recruitment in the US.

The trial is being conducted at 75 sites across 12 countries, with 19 of those sites in the US.

DXB’s Phase 3 study is called “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis” – or ACTION3 for short.

The trial will look into FSGS patients who are already receiving a stable dose of an angiotensin II receptor blocker.

Around 210,000 people worldwide suffer from the rare kidney disease FSGS (Focal Segmental Glomerulosclerosis) each year, with 80,000 of those in the US alone.

Dimerix anticipates first interim analysis to be completed in the first half of 2023.


Other share prices today:



At Stockhead we tell it like it is. While Dimerix is a Stockhead advertiser, it did not sponsor this article.